Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

In a precedential decision issued May 6, 2025, the Federal Circuit reversed in part and vacated in part a Delaware district ...

The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

An advocate for cancer patients has said that patients will "die waiting" for cancer treatments in Ireland after a study ...

State jobs are known for offering competitive benefits and enrollment in the nation’s largest public pension plan.

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...